{
    "Trade/Device Name(s)": [
        "IVD CAPSULE PSP",
        "abioSCOPE"
    ],
    "Submitter Information": "Abionic SA",
    "510(k) Number": "K240041",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070310"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "SCX"
    ],
    "Summary Letter Date": "September 25, 2024",
    "Summary Letter Received Date": "January 5, 2024",
    "Submission Date": "January 3, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Pancreatic Stone Protein (PSP)"
    ],
    "Specimen Type(s)": [
        "K2-EDTA anticoagulated arterial whole blood",
        "K2-EDTA anticoagulated venous whole blood",
        "K3-EDTA anticoagulated venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "abioSCOPE"
    ],
    "Method(s)/Technology(ies)": [
        "Immunofluorescence assay",
        "Nanofluidic biosensor detection"
    ],
    "Methodologies": [
        "Immunofluorescence",
        "Semi-quantitative detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Cartridge",
        "Reagent",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Abionic IVD CAPSULE PSP semi-quantitative immunofluorescence assay for pancreatic stone protein using abioSCOPE analyzer to aid early sepsis detection in adult ICU patients",
    "Indications for Use Summary": "Aids in early detection of sepsis in adult ICU patients at high risk, using semi-quantitative PSP levels from EDTA whole blood with abioSCOPE analyzer, in conjunction with other clinical assessments and laboratory findings",
    "fda_folder": "Microbiology"
}